成立于1907年,是全球成立最早,规模最大的致力于全面、创新和高水平癌症研究的科学组织之一。日前,AACR发布了Cancer Progress Report 2023,编译如下。 在美国,自20世纪90年代以来,癌症总死亡率一直在稳步下降,1991年至2020年期间的死亡率下降避免了380多万癌症患者死亡。 美国癌症总死亡率的下降是由乳腺癌、结肠癌和直...
AACR成立于1907年,是全球成立最早,规模最大的致力于全面、创新和高水平癌症研究的科学组织之一。日前,AACR发布了Cancer Progress Report 2023,编译如下。 在美国,自20世纪90年代以来,癌症总死亡率一直在稳步下降,1991年至2020年期间的死亡率下降避免了380多万癌症患者死亡。 美国癌症总死亡率的下降是由乳腺癌、结肠癌...
"TheAACR Cancer Progress Reportis unique in that it details the remarkable progress made in the past year and provides a clear-eyed assessment of where improvements are needed to help markedly reduce thecancerburden," said David A. Tuveson, MD, Ph.D., FAACR, President of the AACR. "As p...
AACR Cancer Progress Report Pleads for Increased, Stable Research FundingAnis unavailable. This article is available as HTML full text and PDF.doi:10.1097/01.COT.0000407157.30919.c4EastmanPeggyOncology Times
The American Association for Cancer Research (AACR) today released its annual Cancer Progress Report highlighting how federally funded research discoveries are fueling the development of new and even more effective ways to prevent, detect, diagnose, and
, The Grants Register 2024, https://doi.org/10.1057/978-1-349-96073-6 1 2 AACR - American Association for Cancer Research AACR Clinical Oncology Research (CORE) Training Fellowships Purpose: The AACR Clinical Oncology Research (CORE) Training Fellowships Program is designed to provide an ...
The members of the American Association for Cancer Research (AACR) have electedPatricia M. LoRusso, DO, PhD (hc), as the President-Elect for the 2023 to 2024 term. Dr. LoRusso will become President-Elect on Monday, April 17, during the Annual Business Meeting of Members at the A...
马萨诸塞州剑桥,2024 年 3 月 5 日(GLOBE NEWSWIRE)— Foghorn Therapeutics Inc.(纳斯达克股票代码:FHTX)是一家处于临床阶段的生物技术公司,开创了一类通过纠正异常基因表达来治疗严重疾病的新药物。该公司今天宣布,其管道项目的临床前数据,包括首次公布的潜在首创 BRM(SMARCA2)选择性抑制剂 FHD-909 的临床前数据...
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from
today announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller (MYC-EC) in models of EGFR inhibitor (EGFRi)-resistant non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Annual Meeting 2024,...